Aug 20, 2014 10:30 AM ET -
Philadelphia, PA, August 20, 2014 /3BL Media/ – Warfarin, the longtime standard treatment for atrial fibrillation, is facing competition from new options in the anticoagulant drug marketplace including dabigatran, rivaroxaban, and apixaban. A new...
Read More